Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 34 % of short-term debt in 2025; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 26.7 to 20.2.
-
Busy address KBO
24 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
ONCORADIOMICS from Liège, company number BE0662719440, closed financial year 2025 with a result of € 284,677 after tax. For that financial year ONCORADIOMICS recorded a gross margin of € 2.4 million and equity of € -3,807. Compared with financial year 2024, the result moved from € -1.2 million to € 284,677. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.
€ -3,807
▲ € 1 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 284,677
▲ still € 1.2 million loss in 2024
Profit after tax over the fiscal year.
€ 8,698
▼ 99% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -5.1 million.
People and assets in 2025
20.2
▼ 3.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.5 million
▼ 3% vs 2024
€ 74,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 11,996
▼ 63% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 3 million
▼ 15% vs 2024
€ 220,852 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 1 million
▲ 94% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 129,784
▼ 19% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 311,341 | € 876,905 | € 1,261,343 | € 2,368,499 | ▲ 88% |
| Profit after taxes | € -2,367,091 | € -1,902,176 | € -1,151,557 | € 284,677 | ▲ € 1.4 million |
| Equity | € -1,755,454 | € -3,614,843 | € -1,022,246 | € -3,807 | ▲ € 1 million |
| Total debts | € 5,416,653 | € 6,636,004 | € 4,822,353 | € 4,310,567 | ▼ 11% |
| Cash | € 2,199,214 | € 1,200,677 | € 1,002,938 | € 8,698 | ▼ 99% |
| Retained profit | € -2,367,091 | € -4,269,267 | € -5,420,824 | € -5,136,147 | ▲ € 284,677 |
| Bank debt | € 4,380,246 | € 5,286,987 | € 3,565,405 | € 3,032,225 | ▼ 15% |
| Balance sheet total | € 3,661,200 | € 3,021,162 | € 3,800,107 | € 4,306,760 | ▲ 13% |
| Employees (FTE) | 28 | 26.7 | 23.7 | 20.2 | ▼ 3.5 |
Key figures of ONCORADIOMICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ONCORADIOMICS?
What happened at ONCORADIOMICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- DxOrange B.V. BO stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 284,677. Source: NBB ↗
- NOSHAQ PARTNERS SCRL stepped down as director. NBB
- Bernard Surlemont stepped down as director. NBB
- Jörg Stein stepped down as director. NBB
- DxOrange B.V. BO became a director. NBB
- NOSHAQ PARTNERS SCRL became a director. NBB
- Bernard Surlemont became a director. NBB
In short
From € 2.4 million loss in 2022 to € 284,677 profit in 2025.
Paid € 0 in corporate taxes since 2022.
Best year ever: 2025, with € 284,677 profit.
On average € 117,300 of value added per employee in 2025.
A new publication or filing at ONCORADIOMICS? We notify you, reason included.
Follow ONCORADIOMICSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of HI-TECH INVEST, NOSHAQ, BENELUX HEALTH VENTURES comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ONCORADIOMICSThe shares are held by HI-TECH INVEST (49.6%), NOSHAQ (38.8%) and BENELUX HEALTH VENTURES.
Directors
According to the 2025 annual accounts
Director · represented by Johanna Marleen Limbourg
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE, SOGECOM, VITAVERDE.BIO, HAEMERS Technologies, SPACEBEL, NOSHAQ VENTURE +169 more
since 2023 · until 2026
Chairman of the board · represented by Jan Groen
since 2025 · until 2028
since 2023 · until 2026
Jörg Stein
Director
since 2023 · until 2026
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3
4000 Liège
Boulevard de Patience et Beaujonc 3 box 3
4000 Liège
Active since 19 September 2016
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 24 companies are registered at this address.
All companies at this address →Hyloris Developments
€ 5.1 million revenue · 2025
DERMAX
€ 1.6 million revenue · 2025
Hyloris
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals same network
€ 3.8 million revenue · 2025
Hirundo Biosciences same network
€ 0 revenue · 2025
+19 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
AS-HOSTINGER, CY
DNS
Cloudflare DNS
Domain
Domain
radiomics.bio
Registered
2020-12-14
Registrar
OVH SAS
Expires
2026-12-14
Website info
Features
Security
Details
- Company number
- 0662.719.440
- VAT number
- BE 0662.719.440
- Registered office
- Boulevard de Patience et Beaujonc 3, 4000 Liège
- Names & denominations
- ONCORADIOMICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 September 2016
- Peppol
- Active · Active since 1 Dec 2025
- Contact
- radiomics.bio
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied